Cns Drugs

CNS Drugs is a monthly journal published by Adis, part of Springer Nature, that promotes rational pharmacotherapy in clinical psychiatry and neurology,it was founded in 1994 and its 2025 Journal Impact Factor is 7.0《中枢神经系统药物》（CNS Drugs）是（Springer Nature）旗下（Adis）出版的月刊，致力于推动临床精神病学与神经病学中的合理药物治疗，1994 年创办，2025 年影响因子为 7.0。

Scope

• The journal promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology该刊在临床精神病学与神经病学领域推动合理药物治疗。
• It addresses the pharmacology, efficacy and adverse effects of the major classes of drugs used for neurological and psychiatric disorders内容涉及神经与精神疾病主要药物类别的药理学、疗效与不良反应。
• Information on newly developed drugs and drug classes is a standing feature新研发药物与药物类别的最新信息是常设内容。
• It covers the therapeutic implications of the latest research into the aetiology of neurological and psychiatric disorders期刊介绍神经与精神疾病病因学最新研究的治疗学意义。
• The practical management of specific clinical situations is discussed alongside overviews of contentious or emerging issues除对有争议或新出现问题的综述外，还讨论具体临床情境下的实际处理。
• Content includes comprehensive narrative reviews, systematic reviews following PRISMA, Adis Drug Reviews, leading articles and original research closely linked to clinical practice内容包含综合叙述性综述、遵循（PRISMA）的系统综述、（Adis Drug Reviews）、重点文章以及与临床实践密切相关的原创研究。

History

• The journal was founded in 1994 by Adis International and has been published continuously since该刊 1994 年由（Adis International）创办，其后持续出版。
• Adis is part of Springer Nature, and the journal appears under the Springer Healthcare imprint（Adis）隶属（Springer Nature），期刊以（Springer Healthcare）品牌发行。
• It is published monthly and follows a hybrid open access model that does not charge authors for traditional subscription publishing期刊按月出版，采用混合开放获取模式，传统订阅出版不向作者收费。
• It is indexed in the Science Citation Index Expanded in clinical neurology, pharmacology and pharmacy, and psychiatry, as well as in Scopus该刊被（Science Citation Index Expanded）的临床神经病学、药学与精神病学类别以及（Scopus）收录。
• Its Journal Impact Factor moved from 5.749 in 2021 through 6.497 in 2022 and 7.4 in 2024 to 7.0 in 2025, holding Q1 placement in all three of its JCR categories其影响因子由 2021 年的 5.749 经 2022 年的 6.497 与 2024 年的 7.4 变为 2025 年的 7.0，在三个 JCR 类别中均保持 Q1。

Editors

• The editor is Sue Pochon, based at Adis in Springer Nature编辑为（Springer Nature）旗下（Adis）的（Sue Pochon）。
• Adis Drug Reviews, written by the Adis editorial group, cover the properties and place in therapy of both newer and established drugs in neurology and psychiatry由（Adis）编辑团队撰写的（Adis Drug Reviews）栏目，评介神经与精神领域新老药物的特性及其治疗定位。
• Systematic reviews must follow the explicit, systematic methods outlined in the PRISMA statement系统综述须遵循（PRISMA）声明所载的明确、系统的方法。
• Original research articles must report well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research and pharmacoeconomic studies原创研究须为设计良好且与临床实践紧密相关的研究，如临床药动学与药效学研究、临床试验、荟萃分析、结局研究与药物经济学研究。
• The journal also offers additional digital features including animated abstracts, video abstracts and infographics期刊还提供动画摘要、视频摘要与信息图等数字化附加内容。